Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Net Margin of 94.4% for Q1 2026, up 6100.0% year-over-year from 1.52% in Q1 2025, and down 10.66% quarter-over-quarter from 85.3% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Net Margin for 6 consecutive years, with 94.4% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 6100.0% year-over-year to 94.4%; the TTM figure through Mar 2026 stood at 95.71% (up 3142.0% YoY), while the FY2025 annual figure was 106.41%, up 9691.0% from the prior year.
- Net Margin retreated to 94.4% in Q1 2026 per RYTM's latest filing, from 85.3% in the prior quarter.
- Across five years, Net Margin topped out at 527.99% in Q4 2022 and bottomed at 3693.79% in Q1 2022.
- Historically, Net Margin has averaged 420.6% across 5 years, with a median of 155.39% in 2025.
- On a YoY basis, Net Margin climbed as much as 1239263 bps in 2022 and fell as far as 12869379 bps in 2022.
- Rhythm Pharmaceuticals' Net Margin stood at 527.99% in 2022, then plunged by 133 bps to 171.8% in 2023, then soared by 38 bps to 106.7% in 2024, then climbed by 20 bps to 85.3% in 2025, then slipped by 11 bps to 94.4% in 2026.
- Business Quant data shows RYTM's Net Margin at 94.4% in Q1 2026, 85.3% in Q4 2025, and 105.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -70.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.68% |
| Mar 31, 2026 | -94.40% |
| Dec 31, 2025 | -85.30% |
| Sep 30, 2025 | -105.81% |
| Jun 30, 2025 | -98.93% |
| Mar 31, 2025 | -155.39% |
| Dec 31, 2024 | -106.70% |
| Sep 30, 2024 | -135.24% |
| Jun 30, 2024 | -115.42% |
| Mar 31, 2024 | -544.43% |
| Dec 31, 2023 | -171.80% |
| Sep 30, 2023 | -196.25% |
| Jun 30, 2023 | -242.98% |
| Mar 31, 2023 | -454.96% |
| Dec 31, 2022 | 527.99% |
| Sep 30, 2022 | -953.80% |
| Jun 30, 2022 | -523.06% |
| Mar 31, 2022 | -3,693.79% |
| Dec 31, 2021 | -2,975.73% |
| Sep 30, 2021 | -3,727.14% |